Contributors
Evdokia Arkoumani(Princess Alexandra Hospital NHS Trust), Bruce J Youngson, Anita Bane(University Health Network), Emad A. Rakha(Nottingham University Hospitals NHS Trust), James J. Going(The University of Texas Health Science Center), Timothy W. Jacobs(Jacobs (United States)), Gabriela Dontu(University of Michigan), Jonathan J. James(Nottingham University Hospitals NHS Trust), Sunil R. Lakhani(Sullivan Nicolaides Pathology), Jean F. Simpson(Good Samaritan Hospital), Anna Marie Mulligan, Andrew HS Lee(Nottingham University Hospitals NHS Trust), R. Douglas Macmillan(Nottingham University Hospitals NHS Trust), Keith Miller(University College London), Emanuele de Rinaldis(Target (United States)), Donald L. Weaver(University of Vermont), Beverley A. Carter(Government of Newfoundland and Labrador), Ian O. Ellis(University of Nottingham), Jorge S. Reis‐Filho(AstraZeneca (France)), Andrew Tutt(Institute of Cancer Research), John M.S. Bartlett(Edinburgh Cancer Research), Michael Gonzalez(Imperial College Healthcare NHS Trust), Merdol Ibrahim(University College London), David L. Page(Duke University), Frances P. O’Malley(Lunenfeld-Tanenbaum Research Institute), Andrew J. Evans(University of Dundee), Clive Wells, Gavin Harris(Canterbury Health Laboratories), Sarah E. Pinder(St Thomas' Hospital), Sunil Badve(Emory University), A. Fernández Do Nascimento, Bharat Jasani(Cardiff University)
Cited by 0
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k